New Whole Animal ELISA for Angiogenic Drug Screening

Information

  • Research Project
  • 7541282
  • ApplicationId
    7541282
  • Core Project Number
    R43HL088790
  • Full Project Number
    1R43HL088790-01A1
  • Serial Number
    88790
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    9/1/2008 - 16 years ago
  • Project End Date
    2/28/2009 - 15 years ago
  • Program Officer Name
    APPLEBAUM, DEBORAH
  • Budget Start Date
    9/1/2008 - 16 years ago
  • Budget End Date
    2/28/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    8/31/2008 - 16 years ago

New Whole Animal ELISA for Angiogenic Drug Screening

[unreadable] DESCRIPTION (provided by applicant): The overall goal of this research is to develop a rapid, quantitative in vivo assay format for screening angiogenic drug candidates using zebrafish as a model organism. Angiogenesis is well established as a major biological process involved in several pathological conditions, including cancer, diabetic retinopathy, macular degeneration, ischemic heart disease, peripheral arterial disease, and impaired wound healing. However, the lack of understanding of the biological basis of angiogenesis and the lack of assays and animal models have hampered drug development. A significant advantage of the proposed zebrafish assay is that the therapeutic potential of a compound is evaluated in a complex physiological environment with much higher throughput than mammalian in vivo bioassays. Using cell-based screens, this information is impossible to obtain. PUBLIC HEALTH RELEVANCE: Angiogenesis has been shown to be involved in several serious diseases, including diabetes, cancer, heart disease and macular degeneration. This SBIR aims to develop a high throughput quantitative in vivo zebrafish microplate based assay for evaluating angiogenic effects of potential therapeutics. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    135227
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:135227\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    PHYLONIX PHARMACEUTICALS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02139
  • Organization District
    UNITED STATES